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Background: Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist bron-
chodilator currently in Phase III clinical development for the treatment of chronic obstructive
pulmonary disease (COPD). This study evaluated the pharmacodynamics, pharmacokinetics,
safety and tolerability of ascending doses of aclidinium bromide in patients with COPD.
Methods: This double-blind, randomised, placebo-controlled, crossover study was conducted
in patients with moderate to severe COPD (forced expiratory volume in 1 s [FEV1] <65% pre-
dicted). Patients were randomly assigned to one of four treatment sequences of aclidinium
bromide 100, 300, 900 mg and placebo with a washout period between doses. The primary
outcome was area under the FEV1 curve over the 0e24 h time interval.
Results: Seventeen patients with COPD were studied. Mean FEV1 over 24 h was 1.583 L for
placebo, and 1.727 L, 1.793 L and 1.815 L for aclidinium bromide 100, 300 and 900 mg, respec-
tively (p< 0.001 vs. placebo, all doses). Significant changes from baseline in FEV1 were
detected 15 min post-dose for aclidinium bromide 300 and 900 mg, with a peak effect 2 h
post-dose (all doses). Aclidinium bromide was undetected in plasma. The majority of adverse
events was unrelated to study medication and did not result in discontinuation.
Conclusion: Aclidinium bromide 100e900 mg produced sustained bronchodilation over 24 h in
patients with COPD.
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866 G.F. Joos et al.Introduction MethodsChronic obstructive pulmonary disease (COPD) is a prevent-
able and treatable lung disease characterised by chronic
airflow limitation that is not fully reversible.1 COPD is highly
prevalent2 and associated with increased morbidity and
mortality (mainly related to smoking and aging populations2)
as well as reduced quality of life.3,4 The Global Burden of
Disease Study predicts that COPD, the sixth most common
cause of mortality in 1990, will become the third most
common cause of mortality worldwide by 2020.2
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines1 recommend the use of bronchodilators
to improve airflow and reduce breathlessness and state that
long-acting bronchodilators are more effective and conve-
nient than short-acting bronchodilators. For patients with
Stage IIeIV COPD (moderate to very severe COPD), regular
treatment with one or more long-acting bronchodilators is
recommended.1
Only three long-acting bronchodilators are available to
patients with COPD: the b2-agonists formoterol and sal-
meterol, and the anticholinergic tiotropium bromide. COPD
is, therefore, not only a disease with significant morbidity
and mortality, but also has limited treatment options.2,3
Given the serious nature of COPD, and variability in patient
response to medication, there is an important need for
additional pharmacological options.
Aclidinium bromide is a novel, long-acting inhaled
muscarinic antagonist bronchodilator that is being investi-
gated for maintenance treatment of patients with COPD.
Aclidinium bromide was discovered after screening a series
of candidates to identify an agent that combined significant
long-lasting muscarinic M3 receptor binding with low
systemic availability; characteristics considered necessary
to yield compounds with a long duration of clinical effect
and low potential for adverse events (AEs). Receptor
dissociation studies have demonstrated that aclidinium
bromide has a long residence time at the M3 receptor and
a shorter residence time at the M2 receptor.
5 This may be
clinically relevant in patients with COPD since stimulation
of presynaptic M2 receptors serves as a feedback mecha-
nism, inhibiting the release of acetylcholine.6 M2 receptors
also have a prominent role in cardiac function and conse-
quently blockade of these receptors is not desirable.
Additionally, in vitro studies have shown that aclidinium
bromide in human plasma is rapidly hydrolysed (half-life of
2.4 min) to two major inactive metabolites.5 In healthy
subjects (nZ 16), a single dose of aclidinium bromide
resulted in significant, long-lasting (24-h) protection
against methacholine-induced bronchoconstriction.7
The purpose of this study was to assess the pharmaco-
dynamics, pharmacokinetics, safety and tolerability of
single ascending doses of aclidinium bromide (100, 300 or
900 mg) in patients with COPD. The choice of the doses was
based on the results obtained in a phase I trial performed
by our group in healthy volunteers with 50, 300 and 600 mg
and that showed all doses to be safe and well tolerated. As
administration of 50 mg had no effect on airway calibre and
did not offer bronchoprotection, 100 mg was chosen as the
lowest dose for this trial, and 900 mg was chosen as the
highest dose.7Patients
All patients recruited into the study were required to have
a diagnosis of moderate to severe COPD according to the
American Thoracic Society (ATS) guidelines.8 Patients with
a history or evidence of severe allergy (anaphylaxis, angio-
neurotic oedema) or of any kind of chronic or seasonal
allergy (including asthma, urticaria and allergic rhinitis)
were excluded from the study. Patients were men aged
between 40 and 80 years with a smoking history of at least 10
pack-years. Their COPD had to be stable and meet the
following criteria: forced expiratory volume in 1 s (FEV1)
<65% of predicted; a FEV1/forced vital capacity (FVC) ratio
of <70%; and airway reversibility >12% and 200 mL FEV1,
30 min after inhalation of ipratropium bromide 80 mg (Atro-
vent MDI, Boehringer Ingelheim GmbH, Ingelheim,
Germany). Patients with clinically relevant findings on
physical examination, laboratory and electrocardiogram
(ECG) parameters performed at screening visit were
excluded from the study, as were those with significant
disease not related to COPD (including the presence of non-
COPD pulmonary disease or having suffered a myocardial
infarction or stroke within the preceding 6 months). Patients
with common cold or viral infection (in the preceding 4
weeks), or who received any investigational drug one month
prior to study entry or took b-blockers or oral steroids, were
also excluded. Concomitant COPD medications were with-
drawn before the bronchodilator test and each study drug
administration according to the following schedule: short-
acting bronchodilators at least 8 h prior, long-acting bron-
chodilators (b2-agonists) at least 24 h prior, oral b2-agonists
at least 18 h prior and xanthines at least 36 h prior. No long-
acting anticholinergic bronchodilators were available at the
time the study was conducted (February 2001eMay 2002).
Inhaled corticosteroids were permitted if the dose was
stable for at least 4 weeks prior to study entry. Other
medications, mainly for diseases concomitant with COPD,
were permitted if administered at stable doses for at least 3
months prior to study entry. Inhaled salbutamol via propel-
lant metered dose inhaler was allowed during the trial as
rescue medication.
All patients gave their voluntary written informed
consent to participate. The study protocol and consent
forms were approved by the ethics committees of both
participating centres. The study was performed in accor-
dance with the Declaration of Helsinki and ICH GCP
guidelines.
Procedures
This was a two-centre, double-blind, randomised, ascending
single dose, placebo-controlled, crossover trial. Within 14
days of screening visit, eligible patients were randomly
assigned to one of four treatment sequences (i.e. 100, 300,
900 mg or matched placebo) with a washout period of at least
one week between doses. This washout period was consid-
ered sufficient based on the preclinical profile of aclidinium
bromide. Study medication was administered by
capsule inhaler (Cyclohaler, Pharmachemie, Haarlem, The
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and 10:00 am under fasting conditions and at similar times in
each treatment period. The dose range selected in the study
was based on the results of a previous clinical trial per-
formed in healthy volunteers in whom a dose-dependent
response was seen for 50e600 mg with no drug-related AEs.7
To better characterise the aclidinium bromide dose range,
100 mg was selected as the lowest dose. The maximum dose
of 900 mg was chosen to help ensure the maximum effect was
reached.
Lung function tests were performed at screening, pre-
dose, 15, 30, 45, 60 and 90 min, and 2, 4, 6, 8, 10, 12, 24
and 32 h after drug inhalation. The primary outcome
measure was area under the normalised concentration time
curve (AUC) of FEV1 over the 24-h time period (FEV1
AUC[0e24]/24). Secondary measures included AUC of FVC,
peak expiratory flow (PEF) and forced mean expiratory flow
(FEF25e75%). Onset of effect, maximal effect (peak), time to
maximal effect and mean change in FEV1 were calculated.
FVC onset of effect and mean change were also deter-
mined. Lung function tests were performed according to
ATS recommendations.9 At least three measurements were
taken at each time point and the highest value was used for
the analysis.
Blood samples (5 mL) for pharmacokinetic assessments
were collected in heparinised tubes containing the esterase
inhibitor phenylmethylsulphonyl fluoride (PMSF) at pre-
dose, 5, 15, 30, 60 min, 2, 3, 6, 12 and 24 h after every
administration. Aclidinium bromide and its acid and alcohol
metabolites were determined by liquid chromatography/
tandem mass spectrometry (LC/MS/MS). The lower limit of
quantification (LLOQ) was 0.1 ng/mL for aclidinium
bromide and its alcohol metabolite, and 1 ng/mL for the
acid metabolite. All analyses were performed at Almirall,
Barcelona, Spain.
The safety of aclidinium bromide was assessed by means
of physical examination, vital signs (pulse rate and blood
pressure), 12-lead ECG, laboratory data (haematology,
biochemistry and urinalysis) and AEs. Physical examinations
were performed at screening, pre-dose and 24 h post-dose.
AEs, vital signs and ECG were recorded at screening, pre-
dose, and at regular intervals up to 24 h after every drug
administration. Laboratory tests were performed at
screening and 24 h after each administration.Table 1 Patient baseline characteristics (nZ 17).
All patients
Age, years 63.5 (6.2)
BMI, kg/m2 25.6 (2.9)
Predicted FEV1, % 48.8 (11.0)
FEV1, L 1.6 (0.4)
FEV1/FVC 0.5 (0.1)
% bronchial reversibility at 30mina 21.2 (7.5)
Smoking consumption in pack-years 43.8 (20.0)
Pulse rate, BPM 70.2 (10.2)
Systolic blood pressure, mmHg 134.6 (15.8)
Diastolic blood pressure, mmHg 80.6 (8.1)
All values are presented as mean (SD).
Definition of abbreviations: BMIZ bodymass index, BPMZ beats
per minute, FEV1Z forced expiratory volume in 1 sone second,
FVCZ forced vital capacity.
a Reversibility to inhaled ipratropium bromide 80 mg.Statistical analysis
As this was the first trial of aclidinium bromide in patients
with COPD, the number of patients randomised into this
study was based on previous preliminary studies with other
muscarinic antagonists by Maesen et al. (1993)10 and
O’Connor et al. (1996).11 The first of these was a pilot dose-
escalation study in six subjects and the second investigated
the prolonged effect of three doses of tiotropium bromide
on methacholine-induced bronchoconstriction in 12
subjects compared with placebo. In the present study, we
recruited 16 subjects, plus one additional subject to act as
a replacement in case of any withdrawals for reasons other
than drug-related AEs or COPD deterioration.
AUCs were calculated for FEV1, FVC, PEF and FEF25e75%
for the time interval 0e24 h and normalised using thetrapezoidal rule divided by 24.12 The normalised AUCs for
the change from baseline were computed. Statistical
analysis was performed using an analysis of variance
(ANOVA) model for crossover designs including sequence,
patient within sequence period and dose as factors. The
dose effect was estimated using the least square means
with 95% confidence intervals derived from the ANOVA
model. The minimum effective dose was determined when
the factor dose was statistically significant at a 0.05.
Relative change from baseline in FEV1 and FVC was ana-
lysed using a similar ANOVA model but included time as an
additional factor and a time vs. dose interaction term.
Change from baseline in FEV1 and FVC was explored by
means of descriptive statistics. For safety and pharmaco-
kinetic parameters, descriptive statistics were generated
by treatment and dose when applicable.
Results
A total of 17 male Caucasian patients were included in the
study; baseline characteristics are shown in Table 1. One
patient withdrew after the second treatment due to
personal reasons and was replaced; the replacement
patient completed the last two treatments in the sequence.
Five patients received stable doses of inhaled steroids
throughout the study.
Single doses of aclidinium bromide significantly increased
mean FEV1 over the 24-h period compared with placebo
(Table 2). Statistically significant increases in FEV1 and FVC
AUC(0e24)/24 were seen for all three doses of aclidinium
bromide compared with placebo and were seen for both
absolute and mean changes from baseline (Table 2). Change
from baseline in FEV1 AUC(0e24)/24 is shown in Fig. 1.
There were no statistically significant differences
between any of the doses of aclidinium bromide for either
absolute or mean changes from baseline for FEV1 AUC(0e24)/
24 (p 0.172 and0.082, respectively) or FVC AUC(0e24)/24
(p 0.215 and 0.237, respectively).
Mean change from baseline FEV1 from 0 to 4 h and from
0 to 32 h, for each dose, is shown in Fig. 2a and b, respec-
tively. All doses of aclidinium bromide achieved a sustained
Table 2 Normalised area under the concentration time curve over the 24-h time interval (AUC[0e24]/24).
Absolute values Change from baselinea
Placebo Aclidinium
bromide 100 mg
Aclidinium
bromide 300 mg
Aclidinium
bromide 900 mg
Placebo Aclidinium bromide
100 mg
Aclidinium bromide
300 mg
Aclidinium bromide
900 mg
FEV1 (L)
LSM (SE) 1.583 (0.122) 1.727 (0.124) 1.793 (0.123) 1.815 (0.124) 0.024 (0.041) 0.147 (0.049) 0.211 (0.045) 0.186 (0.049)
95% CI 1.321, 1.844 1.462, 1.991 1.530, 2.055 1.557, 2.080 0.109, 0.061 0.047, 0.246 0.119, 0.302 0.087, 0.286
p-Value <0.0001 <0.0001 <0.0001 <0.0001 0.5649 0.0049 <0.0001 0.0005
Comparison vs. placebo
LSM (SE) na 0.144 (0.044) 0.210 (0.040) 0.232 (0.044) na 0.171 (0.047) 0.235 (0.043) 0.211 (0.047)
95% CI 0.056, 0.232 0.129, 0.290 0.144, 0.321 0.076, 0.265 0.149, 0.321 0.116, 0.305
p-Value 0.0021 < 0.0001 < 0.0001 0.0008 < 0.0001 < 0.0001
FVC (L)
LSM (SE) 3.224 (0.197) 3.430 (0.201) 3.491 (0.199) 3.533 (0.201) 0.104 (0.077) 0.360 (0.096) 0.366 (0.085) 0.410 (0.096)
95% CI 2.803, 3.646 3.001, 3.858 3.066, 3.915 3.105, 3.961 0.051, 0.260 0.167, 0.552 0.194, 0.538 0.217, 0.602
p-Value <0.0001 <0.0001 <0.0001 <0.0001 0.1814 0.0005 0.0001 < 0.0001
Comparison vs. placebo
LSM (SE) na 0.205 (0.076) 0.267 (0.069) 0.309 (0.076) na 0.255 (0.101) 0.262 (0.092) 0.305 (0.101)
95% CI 0.052, 0.358 0.127, 0.407 0.156, 0.462 0.051, 0.460 0.076, 0.448 0.101, 0.510
p-Value 0.0099 0.0004 0.0002 0.0158 0.0069 0.0045
Definition of abbreviations: CIZ confidence interval, FEV1Z forced expiratory volume in 1 s, FVCZ forced vital capacity, LSMZ least squares means, naZ not applicable.
a Absolute value minus baseline value.
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Figure 2 (a) Mean (SE) change from baseline in forced
expiratory volume in 1 s (FEV1) over 4 h post-administration.
(b)Mean (SE) change from baseline in forced expiratory volume
in 1 s (FEV1) over 32 h post-administration.
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Bronchodilatory effects of inhaled aclidinium 869bronchodilator effect for up to 24 h as demonstrated by
relative changes from baseline in FEV1 (6.6% for 100 mg,
pZ 0.0191; 14.0% for 300 mg, p< 0.0001; and 9.0% for
900 mg, pZ 0.0076, respectively, vs. placebo at 24 h). In
addition, aclidinium bromide 300 mg had a sustained effect
for up to 32 h (8% improvement in FEV1, pZ 0.0132 vs.
placebo). At 24 h, mean changes from baseline in FEV1 for
aclidinium bromide 100, 300 and 900 mg were þ0.030 L,
þ0.133 L and þ0.131 L, respectively, compared with
0.028 L for placebo. The sustained 24-h bronchodilator
effect of aclidinium bromide was also demonstrated by
increases in FVC both in relative terms and absolute values
(Fig. 3).
Statistically significant bronchodilation was observed as
early as 15 min post-dose (the earliest time point assessed).
Mean increases in FEV1 from baseline at this time point
were 0.122 L for aclidinium bromide 300 mg (relative
changeZ 9.8%; pZ 0.0024) and 0.178 L for aclidinium
bromide 900 mg (relative changeZ 8.6%; pZ 0.0084). At
the lowest dose, this onset of effect was observed at 30 min
with an increase in FEV1 of 0.133 L (relative changeZ 9.4%;
pZ 0.0012). Aclidinium bromide 300 and 900 mg signifi-
cantly increased FVC above baseline within 15 min post-
dose (pZ 0.0006 and 0.0002, respectively), while aclidi-
nium bromide 100 mg significantly increased FVC at 30 min
(pZ 0.0002).
All doses of aclidinium bromide had a time to peak
effect of 2 h post-dose, with a relative change from base-
line in FEV1 of 17.2% after aclidinium bromide 100 mg (mean
increaseZ 0.234 L), 23.3% with aclidinium bromide 300 mg
(mean increaseZ 0.344 L) and 21.4% with 900 mg (mean
increaseZ 0.377 L).
Aclidinium bromide and its alcohol metabolite were
below the LLOQ (<0.1 ng/mL) in plasma following admin-
istration of aclidinium bromide 100, 300 and 900 mg at all
kinetic time points. The acid metabolite, which was the
main compound circulating in plasma, was detected
following administration of aclidinium bromide 900 mg with
peak plasma concentrations (Cmax) of between 3 and 6 ng/
mL achieved approximately 3 h after dosing (tmax). The acid
metabolite was also detected at a limited number of kinetic
time points after administration of aclidinium bromide
300 mg achieving peak plasma concentrations close to theLe
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870 G.F. Joos et al.LLOQ of 1 ng/mL. Due to the very low plasma concentra-
tions of aclidinium bromide and its metabolites, no phar-
macokinetic or statistical analyses were performed.
There were no deaths, serious AEs or discontinuations
due to AEs reported during the study. A total of 28 treat-
ment-emergent AEs were reported in 11 patients during the
study. The majority of AEs were mild (64%) or moderate
(36%) in intensity and three-quarters (21/28) were consid-
ered to be unrelated to the study drug. Seven of these AEs
(25%) were considered possibly related to study drug
(headache nZ 6, increased sweating nZ 1). There was no
relationship between the incidence or severity of AEs,
number of patients reporting an AE and dose. The incidence
of AEs summarised by treatment is shown in Table 3. Single
doses of aclidinium bromide did not result in any clinically
significant changes in vital signs, physical examinations,
laboratory tests or any ECG parameters.
Discussion
The results of this study demonstrate that aclidinium
bromide, a novel inhaled muscarinic antagonist bron-
chodilator, has a significant and long-lasting effect with
a fast onset of action in patients with moderate to severe
COPD.
Aclidinium bromide (100, 300 and 900 mg) significantly
improved pulmonary function as assessed by FEV1 and FVC.
The bronchodilatory effect was sustained for at least 24 h
as demonstrated by AUC FEV1(0e24)/24, the primary endpoint
of the study, and by significant improvements in FEV1
observed over a 24-h period for all doses of aclidinium
bromide. The results of this study are consistent with
receptor dissociation studies5 that provide the rationale for
long-lasting bronchodilation, with a residence half-life at
the M3 receptor for aclidinium bromide of approximately
15 h.Table 3 Adverse events by treatment.
Body system (preferred term) Placebo Aclidinium b
100 mg
Headache 2 2
Myalgia 1
Conjunctivitis 1
Diarrhoea 2
Dyspnoea 1 1
Flatulence 1
Abdominal pain 1
Abrasion NOS 1
Coughing
Dermatitis fungal 1
Dizziness
Epistaxis 1
Haemorrhage rectum
Pain
Pyuria 1
Rhinitis
Sweating increased 1
Total adverse events 8 9
Definition of abbreviation: NOS Z not otherwise specified.Aclidinium bromide 300 and 900 mg produced statisti-
cally significant increases in FEV1 at the earliest time point
measured (15 min). These increases corresponded to
a mean increase in FEV1 of 0.122 L for aclidinium bromide
300 mg and 0.178 L for aclidinium bromide 900 mg. The
similar bronchodilatory results seen with aclidinium
bromide 300 mg and 900 mg were most likely due to the
300 mg dose being sufficient to block the majority of the M3
receptors functionally involved in muscle contraction.
The maximal effect of aclidinium bromide was observed
at 2 h post-dose, with a corresponding mean peak increase
in FEV1 of 17.2%, 23.3% and 21.4% for aclidinium bromide
100, 300 and 900 mg doses, respectively. This maximal
effect of aclidinium bromide is similar to that reported in
the baseline ipratropium reversibility test (21.1% after
30 min, Table 1). However, it should be noted that bron-
chial reversibility was assessed with ipratropium 80 mg,
a dose 2e4 times that usually administered for the main-
tenance treatment of COPD. In a one-year study of patients
with COPD, a maintenance dose of ipratropium 40 mg
improved FEV1 by approximately 0.23 L (19%) 60 min after
the administration of the first dose.13 The improvement in
FEV1 after aclidinium bromide administration observed in
this study is similar to that reported for maintenance doses
of tiotropium bromide. In a single-dose study reported by
Maesen et al., tiotropium bromide over the range 10e80 mg
achieved peak improvements in FEV1 of 19e26%.
14 Further
investigation into the doseeresponse relationship with
aclidinium bromide is needed to establish the optimal dose
range for clinical use. Recently a phase IIb study was pub-
lished, with parallel study design. A total of 464 patients
with moderate to severe stable COPD were randomised to
double-blind, once daily treatment with aclidinium (25, 50,
100, 200 or 400 mg), placebo, or open-label tiotropium
(18 mg) for 4 weeks. It is of interest to note that in this study
also a sustained 24-h bronchodilation was observed, andromide Aclidinium bromide
300 mg
Aclidinium bromide
900 mg
1 1
2
1
1
1
1
1
1
1
3 8
Bronchodilatory effects of inhaled aclidinium 871that the spirometric results observed for aclidinium 200 and
400 mg administered once daily were similar to those
observed with tiotropium 18 mg over the 4 weeks of the
study. On the basis of this study aclidinium 200 mg once
daily was selected for evaluation in phase III studies.15
Significant increases in FVC, a surrogate for decreases in
lung hyperinflation, suggest that aclidinium bromide may
improve dyspnoea, the reason most patients seek medical
attention and a major cause of disability and anxiety asso-
ciated with the disease. No relevant differences in bron-
chodilation were observed in the five patients who received
stable doses of inhaled steroids throughout the study.
Muscarinic receptors exist extensively outside of the
airways and lungs,16 and as systemic exposure to anticho-
linergics may result in undesirable physiological effects,
a key requirement for new inhaled anticholinergics is
minimal systemic exposure. The low concentration of acli-
dinium bromide in plasma observed in this study is consistent
with earlier in vitro data showing that aclidinium bromide is
rapidly hydrolysed to inactive metabolites in human
plasma.5 Consistentwith this very lowand transient systemic
exposure, aclidinium bromide was well tolerated and no
patients withdrew due to an AE. Only seven AEs were
considered to be possibly related to study treatment. There
were no adverse effects commonly associated with anti-
cholinergic muscarinic receptor drugs observed in this study
(e.g. dry mouth, constipation, urinary retention and blurred
vision), which is consistent with the low systemic availability
of aclidinium bromide. The lack of anticholinergic effects
with single doses of aclidiniumbromide is consistentwith the
findings of single-dose studies of tiotropium bromide.10
However, evidence of systemic anticholinergic effects has
been reported with multiple dosing of tiotropium
bromide.17,18 Of further note, single doses of aclidinium
bromide had no clinical effect on ECG parameters.
This studywas performed in a small groupofmalepatients
with known airway reversibility to ipratropium. This inclu-
sion criterionwas selected to ensure that aclidiniumbromide
was being evaluated in patients responsive to inhaled
muscarinic antagonist therapy, rather than investigating the
efficacy of aclidinium bromide in patients non-responsive to
muscarinic antagonists. Recent ATS/European Respiratory
Society (ERS) guidelines on outcomes in clinical studies
conducted with patients diagnosed with COPD19 have sug-
gested that in the assessment of the reversibility of airway
obstruction, a negative response to a single administration of
a bronchodilator should not be used to determine the need
for long-term bronchodilator treatment. The inclusion
criteria used in this study with respect to airway reversibility
are considered to be appropriate for the purpose of this early
Phase II clinical study, i.e. the assessment of pharmacody-
namics, pharmacokinetics, safety and tolerability of single
ascending doses of aclidinium bromide. The results pre-
sented here need to be confirmed in larger studies in patients
representative of the wider COPD population.
In summary, single doses of inhaled aclidinium bromide
had a significant, long-acting bronchodilatory effect with
an early onset of action in patients with COPD. The low
systemic availability of aclidinium bromide may account for
the good tolerability observed in this study. The full ther-
apeutic potential and safety profile of this long-acting
bronchodilator requires further assessment. Findings of thisstudy show the potential for aclidinium bromide as a long-
acting, maintenance treatment for COPD and may provide
an important additional therapeutic option for patients
with COPD.
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